FGFR Gene Alteration clinical trials at UC Irvine

2 in progress, 0 open to eligible people

Showing trials for

  • Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

    Orange, California and other locations

  • FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

    Sorry, not currently recruiting here

    The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Participation could last up to 30 months (2.5 years) and possibly longer if the disease does not get worse.

    Irvine, California and other locations

Last updated: